TRANSSEXUALISM AND OSTEOPOROSIS

The aim of this study was to investigate whether and to what extent ou r regime of cross-gender hormone replacement therapy might influence o steoporosis development in transsexual patients. We found that after l ong-term therapy the bone densities of our cross-gender hormone-treate d transsexual groups (10 male-to-female and 10 female-to-male) did not show significant differences compared to those of the corresponding b iological sex. Moreover, the bone-density during therapy pointed out v ery little variability and that independent of the gender-alteration ( transsexuality-direction) and the age of the transsexuals. Our results indicate that for transsexual patients treated with cross-gender horm one replacement therapy the risk of developing osteoporosis is low.